Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.
Find Clinical Trials & Studies

Vitiligo Study

I'm Interested!

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBOCONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO

  • Sex: Any
  • Age: Adult (18 - 64), Older Adult (65+)
  • Accepting Healthy People: No
  • Type: Interventional / Therapeutic
  • Trial Phase: Phase III
  • Conditions Being Studied:

Study Purpose

The purpose of the study is to evaluate whether the study drug, Ritlecitinib, is effective in managing vitiligo and if it is safe for human use. The study drug will be compared with a placebo, a study drug that does not contain any active ingredients, to find out if the study drug is better than the placebo for the study treatment of vitiligo.

Who Can Participate

Participants 18 years and older diagnosed with non-segmental vitiligo may be eligible for this study.

Principal Investigator
Neil Korman MD PhD
Department/Division
Dermatology (Dermatitis)

Locations

UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106

  • UH IRB: SITE00001967
  • StudyID: 2023-01170
  • ClinicalTrials.gov: NCT05583526
I'm Interested!

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422